Leveraging Vulnerabilities of Molecular Subtypes to Identify Rational Combination Therapies—The Next Wave in Extensive-Stage SCLC?
- 3 July 2026
- journal article
- editorial
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 21 (7) , 103898
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Combination of Lurbinectedin Plus Irinotecan: Preclinical and Early Clinical Results in Patients With Relapsed SCLCJournal of Thoracic Oncology, 2026
- Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?Cancer Treatment Reviews, 2025
- The value and safety of trilaciclib in combination with first-line chemotherapy and immunotherapy for extensive-stage SCLCImmunotherapy, 2025
- Tarlatamab in Small-Cell Lung Cancer after Platinum-Based ChemotherapyNew England Journal of Medicine, 2025
- Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trialThe Lancet, 2025
- Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trialThe Lancet Respiratory Medicine, 2022
- Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilitiesCancer Cell, 2021
- Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trialThe Lancet Oncology, 2020
- Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical modelsBritish Journal of Cancer, 2017
- Damage-associated molecular patterns in cancer: a double-edged swordOncogene, 2016